(Q44725924)

English

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Francesco Panzuto

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Massimo Falconi

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Stefano Partelli

object named as

Stefano Partelli

3

0 references

object named as

Davide Campana

1

0 references

author name string

Gabriele Capurso

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Francesca Nori

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Domenico Tamburrino

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Giulia Cacciari

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Gianfranco Delle Fave

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Paola Tomassetti

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

26 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1197-1205

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

https://scigraph.springernature.com/pub.10.1007/s00259-013-2402-2

0 references

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Multiple actions of somatostatin in neoplastic disease

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2402-2

21 January 2018

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23619938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-013-2402-2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44725924&oldid=2034637414"